NATCOPHARM · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 90/100 — Quality 98 · Valuation 78 · Growth 86 · Momentum 100
| Share price | ₹950.65 |
| Market cap | ₹17,715 Cr |
| P/E ratio | 11.4 |
| P/B ratio | 2.0 |
| ROE | 30.0% |
| ROCE | 30.0% |
| Dividend yield | 0.66% |
| Book value | ₹482.88 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹4,078 Cr | ₹1,418 Cr | 35.0% |
| 2025 | ₹4,430 Cr | ₹1,883 Cr | 50.0% |
| 2024 | ₹3,999 Cr | ₹1,388 Cr | 44.0% |
| 2023 | ₹2,707 Cr | ₹715 Cr | 35.0% |
| 2022 | ₹1,945 Cr | ₹170 Cr | 14.0% |
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and in